Tag:

Thoratec

Latest Headlines

Latest Headlines

Wall Street not anticipating another suitor for Thoratec on heels of St. Jude's $3.4B bid

The consensus is that none of the other medical device bigwigs will try and steal heart pump maker Thoratec from the clutches of St. Jude Medical during the $3.4 billion deal's 30-day "go-shop" period.

UPDATED: St. Jude to buy Thoratec for $3.4B, will pair its heart pump with the cardioMEMs patient monitor

St. Jude Medical announced its intention to acquire Thoratec, the maker of ventricular assist devices that pump the blood of patients awaiting a heart transplant, for $3.4 billion. Its stock price is up 2.5% on the news.

Bloomberg: St. Jude Medical discussing takeover of Thoratec

Industry bigwig St. Jude Medical is discussing a buyout of specialist Thoratec, a maker of left ventricular assist devices, which give heart failure patients awaiting a donated heart a bridge to organ transplantation by pumping their blood in the meantime. Thoratec stock is up 18% to around $58 on the rumor, as of 3 p.m.

Thoratec receives CE mark for new blood pump to assist patients during complex procedures

Thoratec received a CE mark for its HeartMate Percutaneous Heart Pump, following a 30-person clinical trial.

Clinical trial finds Thoratec heart failure device better than medical management

Thoratec touted clinical trial data presented at an International Society for Heart and Lung Transplantation meeting in Nice, France, showing that advanced heart failure patients who receive ambulatory--or outpatient--care are better off using its HeartMate II left ventricular assist device than receiving optimal medical management.

Physicians hesitate to use HeartMate II pump after NEJM study, Thoratec down 30%

Thoratec shed almost one-third of its value after reporting abysmal second quarter earnings. The advanced heart failure device company attributed most of the miss to a New England Journal of Medicine article that came out late last year and linked the company's HeartMate II left ventricular assist device to an increasing rate of pump thrombosis.

Thoratec boosts sales, but profits stay flat

Thanks to its banner HeartMate device, Thoratec handed in another quarter of solid revenue growth, but a spike in costs kept its net income from moving upward.

Thoratec smacked with FDA Class I recall concerning heart pump backup controllers

A formal recall of Thoratec's backup power device used with its HeartMate pumps is now in place, and the FDA slapped a Class I status on the effort, its most serious designation, which means the issue can result in serious injury or death.

Four Thoratec heart pump patients die after struggling with backup controllers

Four patients died and 5 others faced brief scares due to problems involving a backup controller used with Thoratec's HeartMate pumps. The company issued a safety alert to hospitals detailing the issue.

Thoratec's HeartMate pump revenue growth slows to a crawl

Thoratec's revenue stagnated at the end of 2013, but net income grew substantially, thanks in part to the effects of a tax credit. The California company's HeartMate pumps continue to provide the bulk of its revenue.